Norwood Immunology to seek IPO in US
15 November, 2005 by Ruth BeranImmune therapy developer and Norwood Abbey (ASX:NAL) subsidiary Norwood Immunology (AIM:NIM) has revealed plans to seek an initial public offering (IPO) in the USA, subject to market conditions.
Canola taskforce finds small contamination
14 November, 2005 by Graeme O'NeillThe taskforce appointed by the Australian Oilseeds Federation and the Australian Seeds Federation to investigate the recent detection of genetically modified canola seed in a small, non-GM shipment has found the contamination was limited to just one commercial cultivar.
SCS licenses gene expression tech to Lexicon
04 November, 2005 by Ruth BeranStem Cell Sciences (AIM:STEM, SCS) has granted US-based biopharmaceutical company Lexicon Genetics an exclusive license to its Internal Ribosome Entry Site (IRES) technology for genetically modified mice.
Select Vaccines reports promising results for hep C
21 October, 2005 by Susan WilliamsonSelect Vaccines reports promising results for hep C
In brief: Australian Stem Cell Centre, Biotech Capital, Circadian, Alexanders Securities
19 October, 2005 by Ruth BeranProf Vicki Sara has been appointed as director of the Australian Stem Cell Centre and will replace inaugural chairman Robert Moses when he relinquishes the role he has held for three years at the Annual General Meeting (AGM) on November 22. Sara is the chancellor of the University of Technology, Sydney, a fellow of the Australian Academy of Technological Science and Engineering and a former head of the Australian Research Council.
Panbio develops new type of antibody assay
14 October, 2005 by Graeme O'NeillBrisbane medical diagnostics developed Panbio (ASX:PBO) believes it has achieved a milestone in its efforts to develop a new type of antibody assay capable of directly detecting target antigens at low concentrations in antigenically complex biological fluids.
VitroGro now in powdered form
05 October, 2005 by Ruth BeranProtein chemists at Queensland University of Technology (QUT) have produced a new freeze-dried form of Brisbane-based Tissue Therapies' (ASX:TIS) wound-healing technology VitroGro.
Brumby wants therapeutic cloning ban lifted
30 September, 2005 by Ruth BeranVictorian treasurer and minister for innovation, John Brumby, has called on the federal government to lift its ban on somatic cell nuclear transfer (SCNT), otherwise known as therapeutic cloning.
Norwood Immunology granted six patents
29 September, 2005 by Ruth BeranMelbourne immune therapy developer Norwood Immunology (AIM:NIL) has been granted six patents in New Zealand, South Africa and Singapore relating to its technology in key areas such as cancer and infectious diseases.
Bird flu: threat to Australia 'unlikely'
27 September, 2005 by Graeme O'NeillAn Australian expert on influenza believes it is unlikely that migratory birds will carry Asia's lethal H5N1 'bird 'flu' strain to Australia.
Chemeq signs $1.4m sales order
23 September, 2005 by Ruth BeranPerth-based Chemeq (ASX:CMQ) has signed a new sales order for the shipment of CHEMEQ polymeric antimicrobial worth AUD$1.4 million over the next nine months.
Agenix aims to raise $9.85m
19 September, 2005 by Ruth BeranBrisbane-based Agenix (ASX:AGX, NASDAQ:OTC:AGXLY) has lodged a prospectus for an underwritten non-renounceable rights issue to raise $9.85 million before costs.
Four unis to team on plant biotech project
15 September, 2005 by Graeme O'NeillFour Australian universities have made an unusual decision to form a 'virtual company', Meristomics, to commercialise discoveries from basic research in their jointly operated ARC Centre of Excellence for Integrative Legume Research (CILR).
Stem Cell Sciences signs licensing deal with Deltagen
06 September, 2005 by Ruth BeranStem Cell Sciences (AIM:STEM, SCS) has signed a licensing agreement with US-based drug discovery tools and services provider Deltagen for use of its patented internal ribosome entry sites (IRES) technology.
Researchers gear up for stem cell review process
31 August, 2005 by Graeme O'NeillIndividuals and groups opposed to stem cell research have dominated submissions to the Lockhart Legislative Review of Australia's stem cell legislation.
